---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-058025"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:31:34.099798+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# TradeUP Acquisition Corp. extends business combination deadline to August 19, 2023 via $37,433 deposit by Estrella

## Summary
- TradeUP extends deadline to complete initial business combination by one month to August 19, 2023.
- Estrella deposited $37,432.70 ($0.05 per remaining share) into trust account for the extension.
- Deposit funded by unsecured promissory note from TradeUP to Estrella, convertible into shares at $10.00.
- Company may continue monthly extensions up to July 14, 2024.

## SEC filing metadata
- accession: 0001213900-23-058025
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058025/0001213900-23-058025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058025/ea182004-8k425_tradeup.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-058025
- JSON: https://secwatch.observer/filing/0001213900-23-058025.json
- Plain text: https://secwatch.observer/filing/0001213900-23-058025.txt

## Key facts
- Debt Financings
  Estrella Immunopharma, Inc. incurred convertible notes of $37,432.70 with Estrella Biopharma, Inc. at bears no interest maturing upon the consummation of the Company’s business combination.
  - Instrument: convertible notes
  - Principal: $37,432.70
  - Counterparty: Estrella Biopharma, Inc.
  - Rate: bears no interest
  - Maturity: upon the consummation of the Company’s business combination
  - Event: incurrence
  source text: Such deposit is evidenced by an unsecured promissory note in the principal amount of $37,432.70 issued by the Company to Estrella (the “Extension Note”). The Extension Note bears no interest and is payable in full upon the consummation of the Company’s business combination (the “Business Combination”) (such date, the “Maturity Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058025/0001213900-23-058025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.